Debiopharm Innovation Fund: A €141+ million initiative to transform pharma R&D and cancer care innovation

Published on September 29, 2023

Based in Lausanne, Switzerland, the Debiopharm Innovation Fund is the strategic investment arm of the Swiss biopharmaceutical company Debiopharm. With $150 million under management, they recently announced a new seed funding initiative. This initiative aims to support up to 15 seed-stage startups annually. Since its inception in 2006, the fund has invested in 25 companies,…

This content is for members only. Visit the site and log in/register to read.

The post Debiopharm Innovation Fund: A €141+ million initiative to transform pharma R&D and cancer care innovation appeared first on EU-Startups.

Continue reading on website
Other news

Bologna-based Cellply secures €3.6 million setting sights on future growth

September 29, 2023
The Bolognese biotech startup, Cellply, has raised €3.6 million in a recent funding round. The main investors were Recomec, managed by the Zanelli family, LIFTT, and Schia Ventures. It’s worth noting that LIFTT and Schia Ventures have invested in Cellply before, showing their ongoing support for the company. Yet, in the constantly evolving realm of… This content is for members only. Visit the site

38 EFFORTLESS Ways We SAVE MONEY (Without Even Trying)

September 29, 2023
Financial management is often a daunting task in today’s uncertain world. It’s okay to feel that way; you’re not alone. According to a YouGov survey, one in ten consumers does...